SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 325 filers reported holding SEATTLE GENETICS INC in Q2 2019. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $178,845,000 | +94.2% | 913,922 | +68.7% | 0.04% | +76.0% |
| Q2 2020 | $92,080,000 | +48.4% | 541,902 | +0.8% | 0.02% | +19.0% |
| Q1 2020 | $62,050,000 | +1.5% | 537,788 | +0.5% | 0.02% | +31.2% |
| Q4 2019 | $61,137,000 | +54.4% | 535,071 | +15.4% | 0.02% | +45.5% |
| Q3 2019 | $39,599,000 | +28.3% | 463,700 | +4.0% | 0.01% | +37.5% |
| Q2 2019 | $30,865,000 | -7.5% | 445,975 | -2.2% | 0.01% | -11.1% |
| Q1 2019 | $33,381,000 | +27.0% | 455,784 | -1.7% | 0.01% | +12.5% |
| Q4 2018 | $26,281,000 | -27.1% | 463,832 | -0.7% | 0.01% | -11.1% |
| Q3 2018 | $36,032,000 | +18.3% | 467,228 | +1.8% | 0.01% | +12.5% |
| Q2 2018 | $30,457,000 | +23.9% | 458,777 | -2.3% | 0.01% | +14.3% |
| Q1 2018 | $24,576,000 | +4.6% | 469,559 | +6.9% | 0.01% | +16.7% |
| Q4 2017 | $23,491,000 | -1.8% | 439,073 | -0.1% | 0.01% | -14.3% |
| Q3 2017 | $23,910,000 | +8.4% | 439,432 | +3.1% | 0.01% | +16.7% |
| Q2 2017 | $22,048,000 | -18.4% | 426,129 | -0.9% | 0.01% | -14.3% |
| Q1 2017 | $27,024,000 | +23.7% | 429,927 | +3.8% | 0.01% | +16.7% |
| Q4 2016 | $21,847,000 | +8.2% | 414,024 | +10.8% | 0.01% | 0.0% |
| Q3 2016 | $20,187,000 | +19.1% | 373,752 | -10.9% | 0.01% | +20.0% |
| Q2 2016 | $16,956,000 | +9.3% | 419,602 | -5.1% | 0.01% | 0.0% |
| Q1 2016 | $15,517,000 | -24.6% | 442,190 | -3.6% | 0.01% | -16.7% |
| Q4 2015 | $20,582,000 | +16.8% | 458,633 | +0.4% | 0.01% | +20.0% |
| Q3 2015 | $17,620,000 | -10.7% | 456,949 | +12.1% | 0.01% | 0.0% |
| Q2 2015 | $19,727,000 | +42.4% | 407,578 | +4.0% | 0.01% | +25.0% |
| Q1 2015 | $13,858,000 | +13.4% | 392,043 | +3.1% | 0.00% | +33.3% |
| Q4 2014 | $12,219,000 | -13.6% | 380,277 | -0.1% | 0.00% | -25.0% |
| Q3 2014 | $14,146,000 | -54.7% | 380,504 | -53.4% | 0.00% | 0.0% |
| Q2 2014 | $31,234,000 | +67.7% | 816,608 | +99.7% | 0.00% | -20.0% |
| Q1 2014 | $18,629,000 | +12.5% | 408,899 | -1.5% | 0.01% | 0.0% |
| Q4 2013 | $16,566,000 | -57.9% | 415,281 | -53.8% | 0.01% | -16.7% |
| Q3 2013 | $39,372,000 | +193.4% | 898,262 | +110.6% | 0.01% | +50.0% |
| Q2 2013 | $13,420,000 | – | 426,558 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
| Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
| Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
| DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
| Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
| Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
| EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
| CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |